Ionis Pharma Beats Expectations for Q4
The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.
Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the anticipated $135 million. It reported an earnings loss of $0.66 per share, which was also better than the expected loss of $1.11 per share.
Source: Analysts' estimates for the quarter provided by FactSet.
Ionis Pharmaceuticals is a notable biotech business that specializes in the development of RNA-targeted therapeutics. It leverages its antisense technology to develop niche and innovative medicines. Currently, Ionis boasts a strong pipeline, and has prioritized the commercialization of its recently approved products.
